Reading CRVO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRVO free→Reading CRVO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRVO free→QuarterlyIQ Insights · CRVO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Unregistered Sales of Equity Securities The disclosures set forth in
Entry into a Material Definitive Agreement On June 9, 2026, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), for the private placement (the “Private Placement”) of an aggregate of 3,360,377 units (the “Units”), each Unit comprised of (i) (A) one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), or (B)…
Results of Operations and Financial Condition On May 18, 2026, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the three months ended December 31, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Results of Operations and Financial Condition On March 17, 2026, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Results of Operations and Financial Condition On November 10, 2025, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended September 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On October 27, 2025, the Board of Directors (the “Board”) of CervoMed Inc. (the “Company”) appointed David Quigley as a director of the Company. Mr. Quigley, age 58, served at the global consulting firm McKinsey & Company (“McKinsey”) for more than 25 years, including as Senior Partner from 2010 to 2025. While a Senior Partner at McKinsey, Mr. Quigl…
Results of Operations and Financial Condition On August 11, 2025, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended June 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to
Entry into a Material Definitive Agreement On May 12, 2025, CervoMed Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its common stock, par value $0.001 per share, having an aggregate offering price of up to $50,000,000 through the Sales Agent, acting as agent. Pursuant to the Sales Agreement, sales of the Shares may be made by…
Results of Operations and Financial Condition On May 12, 2025, the Company issued a press release announcing financial results as of and for the quarter ended March 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to
Termination of a Material Definitive Agreement To the extent required by
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers To the extent required by
Entry into a Material Definitive Agreement Executive Vice President, Clinical Development On April 14, 2025, the Board of Directors (the “Board”) of CervoMed Inc. (the “Company,” “we” or “us”) appointed Kelly Blackburn, M.H.A., as the Company’s Executive Vice President, Clinical Development, effective April 16, 2025. Ms. Blackburn has previously served as the Company’s Senior Vice President, Clinical Development, since August 2023. Ms. Blackburn’s biography is set forth in our Definitive Prox…
Results of Operations and Financial Condition On March 17, 2025, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit 99.1) is being furnished pursuant to
Importance-ranked changes since the prior daily snapshot.
Total stock risk fell by 12.2 points (from 75.7 to 63.5).
Market risk fell by 12.2 points (from 75.7 to 63.5).
Valuation label changed from 'inexpensive' to 'fair'.
risk label changed from 'high' to 'elevated'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.